Tevogen Bio remains steadfast in its mission to pioneer accessible and affordable precision medicine while advocating for fair and transparent market participation.

On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment (“Series C”). The shares of the Series C have a 7.5% annual dividend and are ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Most outdoor brand logos are bland as a soggy sandwich left out in the rain. But not Patagonia's. Their logo is like a breath of fresh mountain air in a world of corporate stuffiness. I remember the ...